Previous 10 | Next 10 |
2024-02-21 13:11:49 ET More on Emergent Biosolutions Emergent BioSolutions: Q3 Numbers Leave Work To Be Done Emergent BioSolutions extends shelf life of Narcan to 4 years Emergent BioSolutions wins $235.8M DoD contract Seeking Alpha’s Quant Rating on E...
2024-02-21 11:33:14 ET More on Bausch Health Companies Bausch Health: $20bn Debt Is A Mighty Elephant In The Room Bausch + Lomb draws double downgrade at J.P. Morgan on spinoff concerns Bausch gets Chinese approval for Thermage FLX and TR-4 return pad Seeking...
2024-02-21 10:14:39 ET More on Bausch + Lomb Bausch + Lomb Corporation 2023 Q4 - Results - Earnings Call Presentation Hovering Around 52-Week Low, Bausch + Lomb May Be Poised For A Rebound Bausch + Lomb Q4 2023 Earnings Preview Eminence Capital adds Sea, AMD ...
Salix to Provide Scholarships to 10 Students Living with GI Diseases LAVAL, QC / ACCESSWIRE / February 12, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the opening of the 2024 Salix Gastrointestinal Health Scholars Program application period. The program will award...
2024-02-07 18:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
LAVAL, QC / ACCESSWIRE / February 1, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced, as part of its ongoing commitment to board refreshment and board diversity, its nomination of two independent and diverse candidates to stand for election to its Board of Directors at th...
LAVAL, QC / ACCESSWIRE / February 1, 2024 / Bausch Health Companies Inc. (NYSE/TSX:BHC) will release fourth-quarter and full-year 2023 financial results on Thursday, Feb. 22, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide...
LAVAL, QC / ACCESSWIRE / January 30, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced the U.S. launch of CABTREO™ (clindamycin, adapalene, benzoyl peroxide) Topical Gel, 1.2%/0.15%/3.1% indicated for the topical tre...
2024-01-26 08:51:01 ET More on Bausch + Lomb Bausch + Lomb: Not A Good Time To Buy (Rating Downgrade) Bausch + Lomb Corporation (BLCO) Q3 2023 Earnings Call Transcript Bausch + Lomb drops amid comments at JPMorgan Healthcare Conference Bausch + Lomb wins FDA ...
Approval Represents an Important Breakthrough in One of the Largest Medical Aesthetics Markets (*CORRECTION to the release that was posted earlier on January 18, 2024: The TR-4 Return Pad is approved for use by the U.S. Food & Drug Administration (as part of the Thermage FLX device r...
News, Short Squeeze, Breakout and More Instantly...
Bausch Health Companies Inc. Company Name:
BHC Stock Symbol:
NYSE Market:
LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business up...
LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. Court of Appeals for the Federal Circuit in the matter of Salix Pharmaceuticals, LTD. et al v. Norwich Pharmaceutica...
2024-04-11 13:00:03 ET Glen Santangelo from Jefferies issued a price target of $16.00 for BHC on 2024-04-11 11:29:00. The adjusted price target was set to $16.00. At the time of the announcement, BHC was trading at $9.275. The overall price target consensus is at $9.00 w...